Zhigen Hu

705 total citations
9 papers, 222 citations indexed

About

Zhigen Hu is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Zhigen Hu has authored 9 papers receiving a total of 222 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 6 papers in Oncology and 3 papers in Hematology. Recurrent topics in Zhigen Hu's work include Cancer Treatment and Pharmacology (4 papers), Multiple Myeloma Research and Treatments (3 papers) and Cancer therapeutics and mechanisms (2 papers). Zhigen Hu is often cited by papers focused on Cancer Treatment and Pharmacology (4 papers), Multiple Myeloma Research and Treatments (3 papers) and Cancer therapeutics and mechanisms (2 papers). Zhigen Hu collaborates with scholars based in United States, China and Cameroon. Zhigen Hu's co-authors include Bulbul Pandit, Pui‐Kai Li, Dan L. Sackett, Zili Xiao, Andrew M. Lewis, Jiandong Shi, Ping Chen, Karl A. Werbovetz, Chenglong Li and Michael A. Ihnat and has published in prestigious journals such as Blood, Molecular Cancer Therapeutics and Bioorganic & Medicinal Chemistry.

In The Last Decade

Zhigen Hu

9 papers receiving 212 citations

Peers

Zhigen Hu

MB

OC

ONCOL

PS

CR

Michael F. Harte Australia

Xiang Lu China

Christopher Kallus Germany

Meagan B. Rouse United States

Maya Iskandar United States

Tatiana McHardy United Kingdom

Sevil Özcan United States

Kelly M. George United States

T. G. C. Bird Australia

Robert R. Donatelli United States

Michael F. Harte Australia

Zhigen Hu

85 ×0.6

MB

75 ×0.7

OC

36 ×0.9

ONCOL

13 ×0.7

PS

16 ×1.0

CR

Citations per year, relative to Zhigen Hu Zhigen Hu (= 1×) peers Michael F. Harte

Countries citing papers authored by Zhigen Hu

Since Specialization

Citations

This map shows the geographic impact of Zhigen Hu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zhigen Hu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zhigen Hu more than expected).

Fields of papers citing papers by Zhigen Hu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zhigen Hu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zhigen Hu. The network helps show where Zhigen Hu may publish in the future.

Co-authorship network of co-authors of Zhigen Hu

This figure shows the co-authorship network connecting the top 25 collaborators of Zhigen Hu. A scholar is included among the top collaborators of Zhigen Hu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zhigen Hu. Zhigen Hu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

1.

Pandit, Bulbul, Zhigen Hu, Somsundaram Chettiar, et al.. (2013). Structure–activity relationship studies of thalidomide analogs with a taxol-like mode of action. Bioorganic & Medicinal Chemistry Letters. 23(24). 6902–6904. 5 indexed citations

2.

Blackburn, Christopher, Jonathan L. Blank, Frank J. Bruzzese, et al.. (2010). Optimization of a series of dipeptides with a P3 threonine residue as non-covalent inhibitors of the chymotrypsin-like activity of the human 20S proteasome. Bioorganic & Medicinal Chemistry Letters. 20(22). 6581–6586. 39 indexed citations

3.

Blanco, Esperanza J. Carcache de, Bulbul Pandit, Zhigen Hu, et al.. (2007). Inhibitors of NF-κB derived from thalidomide. Bioorganic & Medicinal Chemistry Letters. 17(21). 6031–6035. 18 indexed citations

4.

Pandit, Bulbul, Ping Chen, Dan L. Sackett, et al.. (2006). Structure–activity-relationship studies of conformationally restricted analogs of combretastatin A-4 derived from SU5416. Bioorganic & Medicinal Chemistry. 14(19). 6492–6501. 50 indexed citations

5.

Kuhn, Deborah J., Peter M. Voorhees, Qing Chen, et al.. (2006). Development of Immunoproteasome-Specific Inhibitors as Novel Anti-Cancer Drugs.. Blood. 108(11). 3458–3458. 1 indexed citations

6.

Li, Pui‐Kai, Bulbul Pandit, Dan L. Sackett, et al.. (2006). A thalidomide analogue within vitroantiproliferative, antimitotic, and microtubule-stabilizing activities. Molecular Cancer Therapeutics. 5(2). 450–456. 29 indexed citations

7.

Li, Pui‐Kai, Zili Xiao, Zhigen Hu, et al.. (2005). Conformationally restricted analogs of Combretastatin A-4 derived from SU5416. Bioorganic & Medicinal Chemistry Letters. 15(24). 5382–5385. 21 indexed citations

8.

Shi, Jiandong, Zili Xiao, Michael A. Ihnat, et al.. (2003). Structure–activity relationships studies of the anti-angiogenic activities of linomide. Bioorganic & Medicinal Chemistry Letters. 13(6). 1187–1189. 34 indexed citations

9.

Hu, Zhigen, et al.. (1995). Male gametophyte development inPlumbago zeylanica: cytoplasm localization and cell determination in the early generative cell. PROTOPLASMA. 186(1-2). 79–86. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact